CELG News and Press, Celgene Corporation From 07/31/19

The following slide deck was published by Celgene Corporation in conjunction with their 2019 Q2 earnings Read more ...

Celgene (NASDAQ: CELG ) Q2 results ($M): Revenue: 4,400 (+15.4%). More news on: Celgene Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Celgene (NASDAQ: CELG ): Q2 Non-GAAP EPS of $2.86 beats by $0.24 ; GAAP EPS of $2.16 beats by $0.05 . Revenue of $4.4B (+15.5% Y/Y) beats by $180M . Shares +1% PM. Press Release More news on: Celgene Corporation, Earnings news and commentary, Healthcare stocks news,

Strong total revenue of $4.4 billion, increased 15% Y/Y driven by volume Company raises 2019 total revenue guidance; reaffirms 2020 outlook Fedratinib, ozanimod and luspatercept regulatory filings accepted year-to-date; liso-cel BLA submission on-track for Q4:19 ...

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has granted unconditional approval of Bristol-Myers Squibb’s pending acquisition of Celgene Corporation (NASDAQ:CELG). “Clearance from the European Commission is an important milestone...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Roche's ( OTCQX:RHHBY ) Tecentriq (atezolizumab), combined with chemo and Celgene's (NASDAQ: CELG ) Abraxane [albumin-bound paclitaxel; nab-paclitaxel], for the first-line treatment ...

Quick Take Rapt Therapeutics ( RAPT ) has filed to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement . The firm is focused on developing small-molecule drugs for patients with high unmet clinical needs in oncological and inflammatory disease...

SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP, a nationwide plaintiffs’ law firm dedicated to handling complex class action litigation, announced today that it has reached a $55 million settlement with Celgene Corporation (NASDAQ: CELG) in a long-running cl...

Balloon Takes Flight at the 37 th Annual QuickChek New Jersey Festival of Ballooning to Elevate Importance of Brain Preservation Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) are bringing the MS MindShift: A New View of MS initiative t...

Jounce Therapeutics (NASDAQ: JNCE ) is up  41%  after hours in reaction to its updated partnership with Celgene (NASDAQ: CELG ) under which the latter has in-licensed global rights to JTX-8064, an LILRB2 receptor-targeting monoclonal antibody. More news on: Jounce Therapeutics,...